Non-fusion expression vector capable of enhancing target gene expression and method for preparing non-fusion expression vector
A non-fusion expression and gene expression technology, applied in the field of bioengineering, can solve problems such as improvement
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0032] Example 1 The specific steps for the preparation of GST-containing non-fusion recombinant plasmid pETDuet-GST-CTB / EGF-CTA2-TAT are as follows:
[0033] (1) The plasmid PGEX-4T3 obtained by extraction with a plasmid extraction kit is used as a template, wherein the PGEX-4T3 has the gene sequence of GST. The BamHI-CTB-XhoI fragment was obtained by designing primers and PCR, and the PGEX-INSITE and BamHI-CTB-XhoI were digested by BamHI / XhoI at the same time to obtain the vector fragment and PCR fragment. Ligated overnight, and transformed the ligated product into E. coli BL21(DE3) competent, selected positive clones, and sent them to Shanghai Bioengineering Company for sequencing. The sequencing results showed that CTB was correctly connected to the vector PGEX, and a new plasmid PGEX-CTB was created.
[0034] (2) Using PGEX-CTB as a template, the primer sequences are as follows:
[0035] 5'-CATGCCATGGGTATGTCCCCTATACTAGGTTAT-3' (upstream primer)
[0036] 5'-CCCAAGCTTTTAA...
Embodiment 2
[0043] Example 2 Comparative analysis of EGFP-CTA2-TAT protein expression:
[0044] Transform the plasmids pETduet-GST-CTB / EGFP-CTA2-TAT and pET22b-EGFP-CTA2-TAT into competent cells BL21(DE3) respectively, and select positive transformants by ampicillin-resistant LB plate, and save as glycerol bacteria. Then, the bacterial solution was added into 400mL LB medium containing 100μg / mL at a ratio of 1:100. After culturing for 2h, 1mmol / L IPTG was added to induce expression for 6h, and the protein expression was detected by SDS PAGE and Western Blot (such as figure 2 and 3 shown).
[0045] After SDS PAGE and western blot analysis, it was found that the non-fusion expression of EGFP-CTA2-TAT of the present invention was 20 times higher than the normal expression.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


